<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23261080</PMID><DateCompleted><Year>2013</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-5967</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</Title><ISOAbbreviation>J Clin Virol</ISOAbbreviation></Journal><ArticleTitle>Human enterovirus 71 strains in the background population and in hospital patients in Finland.</ArticleTitle><Pagination><StartPage>348</StartPage><EndPage>353</EndPage><MedlinePgn>348-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcv.2012.11.018</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1386-6532(12)00438-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Human enterovirus 71 (HEV71) is a common cause of severe outbreaks of hand-foot- and mouth disease, aseptic meningitis and encephalitis in Asian populations but has not caused such epidemics in all populations.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To analyze the frequency of HEV71 in the background childhood population in Finland by screening in stool and serum samples and by measuring neutralizing antibodies against HEV71 in serum and to compare the genetic relationship of virus strains detected in asymptomatic children and those causing severe illness in Finland to the strains found in other countries.</AbstractText><AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">4185 stool samples and 5686 serum samples were collected and clinical symptoms recorded from children who were observed from birth. Additional stool samples were available from four children hospitalized due to EV71 infection. Samples were screened for the presence of RNA of human enteroviruses using RT-PCR and HEV71 amplicons were identified by sequencing. Phylogenetic analyses were carried out to study genetic relationships between different virus strains. Neutralizing antibodies against HEV71 were screened from 522 children.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 0.3% of stool samples and two serum samples from healthy children were positive for HEV71 genome. 1.6% of the children had neutralizing antibodies against HEV71. Most infections were asymptomatic or mild in contrast to the clear symptoms in the children hospitalized due to HEV71. All viruses were C strains.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">HEV71 is circulating in Finland but it is rare. No clear difference was seen between strains circulating in the Finnish background population and those found in hospitalized patients or those causing severe outbreaks worldwide.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Honkanen</LastName><ForeName>Hanna</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>University of Tampere, Tampere, Finland. hanna.honkanen@uta.fi</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oikarinen</LastName><ForeName>Sami</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Pakkanen</LastName><ForeName>Outi</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Ruokoranta</LastName><ForeName>Tanja</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Pulkki</LastName><ForeName>Minna M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Laitinen</LastName><ForeName>Olli H</ForeName><Initials>OH</Initials></Author><Author ValidYN="Y"><LastName>Tauriainen</LastName><ForeName>Sisko</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Korpela</LastName><ForeName>Sanna</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lappalainen</LastName><ForeName>Maija</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vuorinen</LastName><ForeName>Tytti</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Haapala</LastName><ForeName>Anna-Maija</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Veijola</LastName><ForeName>Riitta</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Simell</LastName><ForeName>Olli</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Ilonen</LastName><ForeName>Jorma</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Knip</LastName><ForeName>Mikael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hy&#xf6;ty</LastName><ForeName>Heikki</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Clin Virol</MedlineTA><NlmUniqueID>9815671</NlmUniqueID><ISSNLinking>1386-6532</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003428" MajorTopicYN="N">Cross Infection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005387" MajorTopicYN="N" Type="Geographic">Finland</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23261080</ArticleId><ArticleId IdType="doi">10.1016/j.jcv.2012.11.018</ArticleId><ArticleId IdType="pii">S1386-6532(12)00438-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>